Your browser doesn't support javascript.
loading
Clinical potential of psilocybin as a treatment for mental health conditions.
Daniel, Jeremy; Haberman, Margaret.
Afiliação
  • Daniel J; Assistant Professor, South Dakota State University College of Pharmacy, Sioux Falls, South Dakota; Psychiatric Clinical Pharmacist, Avera Behavioral Health Center, Sioux Falls, South Dakota, Jeremy.Daniel@avera.org.
  • Haberman M; Psychiatric Clinical Pharmacist, Avera Behavioral Health Center, Sioux Falls, South Dakota.
Ment Health Clin ; 7(1): 24-28, 2017 Jan.
Article em En | MEDLINE | ID: mdl-29955494
ABSTRACT
Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol use disorder, and tobacco use disorder. This article provides an in-depth review of the study design and results of psilocybin in each of these conditions and discusses the clinical potential for use.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ment Health Clin Ano de publicação: 2017 Tipo de documento: Article País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ment Health Clin Ano de publicação: 2017 Tipo de documento: Article País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA